For patients in that second category, peptide therapy is increasingly part of the conversation, and two compounds come up most often: BPC-157 and TB-500
NAD Plus and the Mitochondrial Side Technically not a peptide but a coenzyme sharing menu items and a mechanistic neighborhood is NAD+
Toilet Paper: Regular toilets are basic
Nope, go to the gym or get liposuction
Both compounds share the same regulatory timeline: moved to Category 2 in 2023, removed from Category 2 in April 2026, and scheduled for PCAC review on July 23, 2026
Today, individuals who have been diagnosed with blood clots, DVTs, and pulmonary embolisms, after using Ozempic have filed lawsuits, taking legal action against the manufacturer